



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,125	11/21/2003	Franz Birke	01-1421	2235
28501	7590	05/16/2008	EXAMINER	
MICHAEL P. MORRIS			HENLEY III, RAYMOND J	
BOEHRINGER INGELHEIM CORPORATION				
900 RIDGEURY ROAD			ART UNIT	PAPER NUMBER
P. O. BOX 368			1614	
RIDGEFIELD, CT 06877-0368				
			MAIL DATE	DELIVERY MODE
			05/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/719,125	BIRKE ET AL.	
	Examiner	Art Unit	
	Raymond J. Henley III	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 25 April 2008.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 3 and 9-18 is/are pending in the application.

4a) Of the above claim(s) 9-12 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 3 and 13-18 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____.	6) <input type="checkbox"/> Other: _____ .

CLAIMS 3 AND 9-18 ARE PRESENTED FOR EXAMINATION

On April 8, 2008, a request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Because this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114.

Applicants' submissions filed on April 8 & 25, 2008 has been entered. Accordingly, claims 3, 9, 11, 13, 15, 16 and 18 have been amended. Accordingly, the rejection of claim 18 under 35 U.S.C. § 112, second paragraph has been overcome and thus is withdrawn.

Restriction Requirement

As per the requirement for restriction dated August 31, 2006, claims 9-12 remain withdrawn from consideration under 37 CFR § 1.142(b) as being directed to non-elected subject matter. Claims 3 and 13-18 are herein acted on the merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejection - 35 USC § 103

Claims 3 and 13-17 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Anderskewitz et al., (U.S. Patent No. 5,731,332, cited by Applicants) in view of Gregory et al., (U.S. Patent No. 6,172,096, cited by Applicants), each of record, for the reasons of record as set forth in the previous Office action dated November 9, 2007, which reasons are here incorporated by reference.

Applicants' remarks at pages 6-8 of the amendment referenced at the outset of this Office action, as well as the claim amendment which recite that the compound of formula 1A to meloxicam is present at a ratio of 1:20 have been carefully considered, but fail to persuade the Examiner of error in maintaining this rejection.

Applicants have traversed the present rejection on the basis that the prior art fails to teach or suggest the allegedly synergistic results shown in the present specification and, in light of the Examiner's previous comments as well as the amendments to the claims, that the scope of the claims and of the data are commensurate.

The Examiner continues to acknowledges that the specification at page 16, lines 20-25 establishes a super-additive result which would not have been expected from the teachings of the prior art. The present claims, however, continue to not be commensurate in scope with these results.

Dosage Amounts/Ratios

In particular, claim 3 contains a limitation that the compound of formula 1A to meloxicam is present at a ratio of 1:20. Also, claim 15 recites a range of ratios of active agents while claim 16 recites a range of milligram amounts for the combination of actives. Unexpected results, however, have only been shown where the actives were employed in a ratio of LTB4 antagonist:meloxicam of 1:20 and also when administered in a range of rates of administration which varied and were from 0.1 mg/kg formula IA / 2mg/kg meloxicam to 0.8 mg/kg formula IA / 16 mg/kg meloxicam. None of the claims accurately reflect the ingredient ratio and amounts.

Applicants have offered that because unexpected results were shown over a range of dosages, "the data also suggests the synergistic effect would be maintained over a range of

weight ratios”, (amendment pg. 8). This position, however, is based solely in speculation. Also, it has not been explained how the test data is to be interpreted so that one would necessarily arrive at the particular range of ratios as in claim 15.

Thus, the claims are not seen to be quantitative commensurate in scope with the evidence present in the specification.

Composition of Matter Not Unexpected

The unexpected results relating to the treatment of inflammation demonstrated in the present specification are only realized when one practices a method of treating inflammation which includes a step of administering the active agents to a host. The present claims, however, are directed to compositions of matter and thus are not limited by an intended use or function or a step of administration, (see MPEP § 2111.02(II)). Thus, even if the present claims were limited to the actual dosage amounts which provided the synergistic, anti-inflammatory results, the present claims would remain not commensurate in scope with such results.

Accordingly, for the reasons above, the claims are properly rejected and none are in condition for allowance.

This is a continued examination of Application No. 10/719,125. All claims are drawn to the same invention as previously claimed and could have been finally rejected on the grounds and art of record in the next Office action if they had been presented in response to a first action on the merits. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action following a Request for Continued Examination in this case. See MPEP § 706.07(b). Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1614

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond J. Henley III whose telephone number is 571-272-0575. The examiner can normally be reached on M-F, 8:30 am to 4:00 pm Eastern Time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Raymond J Henley III/
Primary Examiner, Art Unit 1614

May 13, 2008